



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

Publication number: 0 581 187 A1

EUROPEAN PATENT APPLICATION


Application number: 93111685.1  
Date of filing: 21.07.93  
Int. Cl. C07C 251/54, C07C 239/20, C07D 213/53, C07D 401/06

Priority: 21.07.92 JP 215457/92  
Date of publication of application: 02.02.94 Bulletin 94/05  
Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
Applicant: ONO PHARMACEUTICAL CO., LTD.  
1-6, Doshomachi 2-chome  
Chuo-ku  
Osaka-shi Osaka(JP)  
Inventor: Hamaoka, Nobuyuki, c/o Ono Pharmaceutical Co. Ltd  
Kinase Research Inst.  
3-1-1 Sakurai Shimamoto-cho  
Osaka-shi Osaka(JP)  
Representative: Hentzel, Feller, Hünzel & Partner  
Mühlstrasse 37  
D-81675 München (DE)

Mishima-gun, Osaka(JP)  
Inventor: Takahashi, Kanji, c/o Ono Pharmaceutical Co. Ltd  
Kinase Research Inst.  
3-1-1 Sakurai Shimamoto-cho  
Mishima-gun, Osaka(JP)  
Inventor: Tokumoto, Hidetada, c/o Ono Pharmaceutical Co. Ltd  
Kinase Research Inst.  
3-1-1 Sakurai Shimamoto-cho  
Mishima-gun, Osaka(JP)

Oxime derivatives.

An oxime derivative (I):



D ring and B bonding to D ring are (i)-(iv), wherein R1 is hydrogen, lower alkyl; R2 is hydrogen, alkyl, phenyl, cycloalkyl, monocyclic ring containing nitrogen, lower alkyl substituted by benzene ring or cycloalkyl, lower alkyl substituted by monocyclic ring containing nitrogen; R3 is alkyl, phenyl, cycloalkyl, monocyclic ring containing nitrogen, lower alkyl substituted by benzene ring or cycloalkyl, lower alkyl substituted by monocyclic ring containing nitrogen; e is 3-5, f is 1-3, p is 1-4, q is 1-2, r is 1-3; the position of the bond to D ring in (iii) and (iv) is a or b, and the ring in R2 and R3 may be substituted by lower alkyl, alkoxy, halogen, nitro, trifluoromethyl; and salts thereof.


possesses an agonistic activity on PG2 receptor, so it is expected to be useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertension.

Printed at: (UK) Business Services  
G 10/158/33.41

EP 0 581 187 A1

Summary


This invention is related to an oxime derivative.  
More particularly, this invention is related to:  
1) an oxime derivative of the formula (I):



wherein all the symbols are the same meaning as hereafter defined, and non-toxic salts thereof,  
2) processes for the preparation thereof and  
3) pharmaceutical agents containing them as active ingredient.  
4) methods of prevention and treatment by administering them to the patient to be treated.

Background of the invention

Prostaglandin H<sub>2</sub> (PGH<sub>2</sub>) is a physiologically active natural substance having the following structural formula, which is biosynthesized from Prostaglandin H<sub>2</sub> (PGH<sub>2</sub>) in the metabolic process in vivo called arachidonate cascade.



(see Nature, 263, 683(1978), Prostaglandins, 12, 685(1978), *ibid.*, 12, 915(1978), *ibid.*, 13, 3(1977) and Chemical and Engineering News, Dec. 20, 17(1976)).

PGH<sub>2</sub> has been confirmed to possess not only a very strong inhibitory activity on blood platelet aggregation but an inhibitory activity on blood platelet adhesion, a vasodilating activity, an inhibitory activity on gastric acid secretion etc. Therefore, it has been considered that PGH<sub>2</sub> is useful for the prevention and/or the treatment for thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer, hypertension etc. But its application for pharmaceuticals is limited because of its chemical instability and difficulty of separation of the actions according to purpose. Accordingly, various PGH<sub>2</sub> derivatives have been synthesized and many researches have been carried out for the maintenance and the separation of the actions. However, we have not satisfactory results yet.


Recently, in order to solve two problems above described, the research for PG<sub>2</sub> receptor agonists which don't have PG skeleton has been carried out.

Related Arts


It has been reported in the literatures, that the following compounds not having the PGH<sub>2</sub> skeleton are PG<sub>2</sub> receptor agonists which bind to a PG<sub>2</sub> receptor and inhibit blood platelet aggregation:

BEST AVAILABLE COPY


EP 0 581 187 A1



10 (see Brit. J. Pharmacol., 76, 423(1982), *ibid.*, 84, 595(1985), *ibid.*, 88, 643(1985), and the Japanese Patent Kohyo No. 55-501098),



(see Brit. J. Pharmacol., 76, 423(1982), *ibid.*, 84, 595(1985), *ibid.*, 88, 643(1985), and the Japanese Patent Kohyo No. 55-501127),




(see Brit. J. Pharmacol., 102, 251-266(1991) and the West German Patent Publication No. 3,504,877).

#### Disclosure of the Invention

40 The present invention is related to :





1) an oxime derivatives of the formula (I):



wherein



is



R<sup>1</sup> is hydrogen or C1-4 alkyl ;

R<sup>2</sup> is

(i) hydrogen,

(ii) C1-8 alkyl,

(iii) phenyl or C4-7 cycloalkyl,

(iv) 4-7 membered monocyclic ring containing one nitrogen,

(v) C1-4 alkyl substituted by benzene ring or C4-7 cycloalkyl or

(vi) C1-4 alkyl substituted by 4-7 membered monocyclic ring containing one nitrogen ;

R<sup>3</sup> is

(i) C1-8 alkyl,

(ii) phenyl or C4-7 cycloalkyl,

(iii) 4-7 membered monocyclic ring containing one nitrogen,

(iv) C1-4 alkyl substituted by benzene ring or C4-7 cycloalkyl or

(v) C1-4 alkyl substituted by 4-7 membered monocyclic ring containing one nitrogen ;

o is 3-5, t is 1-3, p is 1-4, q is 1 or 2, r is 1-3;

with the proviso that, when





[illegible]

acid,  
[5-(2-*t*-phenyl-1-(3-pyridyl)methylaminoxy)jethyldiene]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
[8-(2-*t*-phenyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,

6 [5-(2-*t*-pentyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,  
[5-(2-*t*-pentyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
[5-(2-*t*-pentyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,

10 [5-(2-1'-cyclohexyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-  
acetic acid,  
[5-(2-1'-cyclohexyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,

15 [5-(2-1'-cyclohexyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-  
acetic acid,  
[5-(2-1'-cyclopentylmethyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-  
yloxy]acetic acid,  
[5-(2-1'-cyclopentylmethyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-  
yloxy]acetic acid,

20 [5-(2-1'-benzyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,  
[5-(2-1'-benzyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,

25 [5-(2-1'-benzyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,  
[5-(2-1'-phenyl-1-(4-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,  
[5-(2-1'-phenyl-1-(4-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
[5-(2-1'-phenyl-1-(4-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,


30 [5-(2-1'-phenyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-  
acetic acid,  
[5-(2-1'-phenyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,

35 [5-(2-1'-phenyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-  
acetic acid,  
[5-(2-1'-phenyl-1-(3-pyridyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid,


40 [5-(2-1'-phenyl-1-(3-pyrrolylmethyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic  
acid and  
[5-(2-1'-phenyl-1-(3-pyrrolylmethyl)(methyldeneaminooxy)jethyldiene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-  
acetic acid.

## 45 Process for the Preparation

In the compounds of the present invention of the formula (I), compounds wherein R<sup>1</sup> is hydrogen, of the formula (Ia) :




wherein all the symbols are the same meaning as hereinbefore defined, may be prepared by hydrolysis in an alkaline condition of a compound of formula (Ib) :




wherein R<sup>1a</sup> is C1-4 alkyl.

Hydrolysis of ester in an alkaline condition is known reaction, for example, it may be carried out in a water-miscible organic solvent (tetrahydrofuran, dioxan, ethanol, methanol, dimethoxyethane or two or more of the mixture thereof etc.), using an aqueous solution of alkali (sodium hydroxide, potassium hydroxide etc.), at -10 to 70 °C.

In the compounds of the formula (Ib), compounds of the formula (Ib-1):



wherein all the symbols are the same meaning as hereinbefore defined, may be prepared by reduction of a compounds of formula (Ib-2) :



wherein all the symbols are the same meaning as hereinbefore defined.

Reduction of imino group into amino group is known reaction, for example, it may be carried out in a water miscible organic solvent (tetrahydrofuran, dioxan, ethanol, methanol, dimethoxyethane or two or more of the mixture thereof etc.), in the presence of an acid (hydrochloric acid, acetic acid, trifluoroacetic acid etc.), using a reducing agent (sodium cyanoborohydride etc.), at 0 to 70 °C.

Compounds of the formula (Ib-2) may be prepared by reacting a compound of formula (II) :



wherein X is halogen or mesyloxy, and the other symbols are the same meaning as hereinbefore defined, and a compound of formula (III) :




wherein all the symbols are the same meaning as hereinbefore defined.

The reaction of halogenated alkyl and hydroxylamine is known reaction, for example, it may be carried out in an inert organic solvent (dimethylformamide, hexamethylphosphoramide, dimethoxyethane or two or more of the mixture etc.), in the presence of a base (sodium hydride, potassium t-butoxide, etc.), at 0 to 90 °C.

The compound of the formula (II) is known compound, for example, they are disclosed in the specification of Japanese Patent Application No. 4-208587. They may also be prepared by the series of reaction described in scheme A shown below.

In the scheme A, Ms is mesyl, X<sup>1</sup> and X<sup>2</sup> is independently halogen, and the other symbols are the same meaning as defined hereinbefore.

## Reaction Scheme A



## Starting materials

The starting materials and each reagent in process for the preparation of the present invention are known per se, or may be prepared by methods known per se. In each reaction in the present specification, products may be purified by conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

## Pharmacological Activities

It has been confirmed that the compounds of the present invention of the formula (I) possess an agonistic activity on  $PGU$  receptor by the following experimental results.

i) Inhibitory activity on binding of  $[^3H]$ -iloprost to  $PGU$  receptor on human blood platelet membrane fraction

## Method

50 mM Tris-HCl buffer (pH 7.4) containing 15 mM  $MgCl_2$ , 5 mM EDTA and 10 nM  $[^3H]$ -iloprost were used as reaction medium. To 0.2 ml of the reaction medium, human blood platelet membrane fraction (0.3 mg protein) was added with or without a test compound. The mixture was incubated at  $24^\circ C$  for 30 min. After incubation, the reaction mixture was filtered through glass fiber filter to separate bound and free  $[^3H]$ -iloprost. The radioactivity was counted, and bound  $[^3H]$ -iloprost was calculated.

Specific  $[^3H]$ -iloprost binding was calculated by subtracting the non-specific binding from the total binding. Non-specific binding was obtained by performing parallel binding experiments in the presence of non-labeled iloprost ( $10 \mu M$ ).

The inhibitory effect of test compound was calculated from the following equation.

The percentage of inhibition (%) =  $100 - (B_1/B_0 \times 100)$

$B_1$  : specific  $[^3H]$ -iloprost binding in presence of test compound  
 $B_0$  : specific  $[^3H]$ -iloprost binding in absence of test compound

The results are shown in the following table 1.

Table I

Example No.	$IC_{50}(\mu M)$
2	0.33
2(a)	0.21
2(g)	0.31
2(i)	2.5

ii) Inhibitory effect on human blood platelet aggregation

## Method

Platelet-rich plasma (PRP) was prepared from human blood ( $5 \times 10^5$  platelets /  $mm^3$ ), and a test compound was added to PRP 1 min prior to the addition of ADP ( $4 \mu M$ ). The aggregation was monitored by a change of the permeability, using a platelet aggregometer (NGS HEMA TRACER 601, Niko Bioscience, Japan).

The results are shown in the following table 2.

Table II

Example No.	$IC_{50}(\mu M)$
2(a)	0.12
2(d)	0.074
2(e)	0.047
2(g)	0.013

## Toxicity

The toxicity of the compounds of the present invention is very low and therefore, it may be confirmed that the compounds of the present invention are safe for pharmaceutical use.

# Application for Pharmaceuticals

The compounds of the present invention, of the formula (I) possess an agonistic activity on PG12 receptor, and therefore are useful for the prevention and/or the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertension, etc.

For the purpose above described, the compounds of the formula (I), of the present invention, non-toxic salts thereof, and hydrates thereof may be normally administered systemically or partially, usually by oral or parenteral administration.

The doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 µg and 100 mg, by oral administration, up to several times per day, and between 0.1 µg and 10 mg, by parenteral administration (preferable intravenous administration), up to several times per day, or continuous administration between 1 and 24 hrs. per day from vein.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

When administration of the compounds of the present invention, it is used as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

Capsules include hard capsules and soft capsules.

In such compositions, one or more of the active compound(s) is or are admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium measilicate aluminates, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents, and assisting agents for dissolving such as glutamic acid, etc.).

The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, etc.), or be coated with more than two films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s) commonly used in the art (Purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavouring agents, perfuming agents, and preserving agents.

Other compositions for oral administration included spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfate etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the United States Patent No. 2,868,691 or 3,065,355 (herein incorporated in their entireties by reference) may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions, suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions, suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, alcohol such as ethanol, POLYSORBATE® (registered trade mark), etc.

Injections may comprise additional other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent, assisting agents such as assisting agents for dissolving (glutamic acid, asparaginic acid, etc.).

They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions and which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before used.

Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointment, suppositories for rectal administration and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by per se known methods.

# Reference examples and Examples


The following reference examples and examples illustrate the present invention, but not limit the present invention.

The solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations.

Unless otherwise specified "NMR" were measured in a solution of CDCl<sub>3</sub>.

## Example 1

Synthesis of [5-[2-(1'-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl]-5,6,7,8-tetrahydronaphthalen-1'-yloxy]-acetic acid methyl ester




Phenyl-(2-pyridyl)methylidenehydroxylamine (269 mg) was added to a suspension of sodium hydride (34.1 mg) in dimethylformamide (3 ml), under an atmosphere of argon, at room temperature. The mixture was stirred for 30 min. The reaction mixture was added dropwise to a solution of [5-(2-bromoethyl)-5,6,7,8-tetrahydronaphthalen-1'-yloxy]acetic acid methyl ester (355 mg) in dimethylformamide (5 ml). The mixture was stirred overnight. A saturated aqueous solution of ammonium chloride was added to the reaction mixture. The mixture was extracted with ether. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried and evaporated. The residue was purified by silica gel column chromatography to give the title compound (463 mg) having the following physical data.

NMR: δ 8.87-8.48 (3H, m), 7.88-7.56 (1H, m), 7.56-7.15 (5H, m), 7.00 (1H, t), 6.72 (1H, d), 6.47 (1H, d), 4.59 (2H, s), 4.30 (2H, t), 3.78 (3H, s), 3.06-2.58 (3H, m), 1.96-1.48 (8H, m); MS: m/e 444(M<sup>+</sup>), 385, 371

## Example 1(a)

Synthesis of [5-[2-(diphenylmethylideneaminoxy)ethyl]-5,6,7,8-tetrahydronaphthalen-1'-yloxy]acetic acid methyl ester



By the same procedure as described in example 1, the title compound having the following physical data was given.


TLC: Rf 0.28 (ethyl acetate : hexane = 1 : 5);

NMR: δ 8.78-7.2 (10H, m), 7.03 (1H, t), 6.78 (1H, t), 6.50 (1H, d), 4.62 (2H, s), 4.30 (2H, t), 3.80 (3H, s).

3.0-2.5 (3H, m), 2.2-1.8 (6H, m)

**Example 2**

6 Synthesis of [5-(2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-acetic acid



20 1N aqueous solution of sodium hydroxide (2 ml) was added to a mixture of the compound prepared in example 1 (460 mg) in tetrahydrofuran-methanol (8 ml + 3 ml). The mixture was stirred for 40 min. The reaction mixture was neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried and evaporated. The residue was purified by silica gel column chromatography to give the title compound (189 mg) having the following physical data.


TLC: Rf 0.48 (methanol : methylene chloride = 1 : 9) ;

NMR:  $\delta$  8.8-8.5 (2H, m), 7.87 and 7.77 (1H, dd), 7.5-7.3 (8H, m), 7.1-6.8 (1H, m), 6.8-6.7 (1H, m), 6.7-6.2 (2H, m), 4.50 (2H, s), 4.30 (2H, t), 3.0-2.5 (3H, m), 2.2-1.8 (2H, m)

30 By the same procedure as described in example 1 and 2, using the corresponding compound, the following compounds having the following physical data was given.

**Example 2(a)**

35 [5-(2-(diphenylmethylideneaminoxy)ethyl)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid




TLC: Rf 0.17 (methanol: methylene chloride = 1 : 10) ;

50 NMR:  $\delta$  7.6-7.2 (10H, m), 7.05 (1H, t), 6.80 (1H, d), 6.53 (1H, d), 4.65 (2H, s), 4.30 (2H, t), 3.0-2.5 (3H, m), 2.2-1.8 (6H, m)

**Example 2(b)**

10 [1-(2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl)-2,3-dihydroinden-4-yloxy]acetic acid




TLC: Rf 0.44 (20% MeOH/CH2Cl2);

NMR:  $\delta$  8.88 and 8.58 (1H, s), 8.60 and 8.55 (1H, d, J = 7Hz), 7.85-7.81 and 7.76-7.72 (1H, m), 7.50-7.28 (6H, m), 7.13-7.04 (1H, m), 6.88-6.80 (1H, m), 6.82-6.57 (1H, m), 4.55 (2H, s), 4.38-4.27 (2H, m), 3.23-3.13 (1H, m), 3.00-2.90 (1H, m), 2.86-2.75 (1H, m), 2.32-2.17 (2H, m), 1.85-1.63 (2H, m).

**Example 2(c)**

25 [6-(1-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)methyl)-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid




TLC: Rf 0.51 (20% MeOH/CH2Cl2);

NMR:  $\delta$  8.87 and 8.61 (1H, s), 8.58 and 8.54 (1H, d, J = 7Hz), 7.85-7.78 and 7.76-7.68 (1H, m), 7.50-7.25 (8H, m), 7.00-6.82 (1H, m), 6.74-6.63 (1H, m), 6.59-6.50 (1H, m), 4.46 (2H, s), 4.25-4.10 (2H, m), 3.00-2.88 (1H, m), 2.86-2.73 (1H, m), 2.67-2.51 (1H, m), 2.51-2.40 (1H, m), 2.23-2.12 (1H, m), 2.00-1.87 (1H, m), 1.53-1.30 (1H, m)

**Example 2(d)**

40 [8-(1-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)methyl)-7,8-dihydronaphthalen-1-yloxy]acetic acid




TLC: Rf 0.29 (MeOH/CH2Cl2 = 1/5);

NMR:  $\delta$  8.70-8.50 (2H, m), 7.88-7.70 (1H, t, J = 8Hz), 7.07 (1H, t, J = 8Hz), 6.70 (1H, d, J = 8Hz), 6.65 (1H, d, J = 8Hz), 6.39 (1H, s), 4.80 (2H, s), 4.62 (2H, s), 2.91 (2H, t, J = 8Hz), 2.37-2.20 (2H, s).




Example 2(c)


[5-[2-(1-(3-dipyridyl)methylideneaminoxy)ethyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid

TLC: Rf 0.25 (20% MeOH/CHCl<sub>3</sub>);NMR:  $\delta$  8.78-8.60 (4H, m), 7.80-7.68 (2H, m), 7.60-6.50 (1H, brs), 7.45-7.28 (2H, m), 7.03 (1H, t, J=8Hz), 6.73 (1H, d, J=8Hz), 6.56 (1H, d, J=8Hz), 4.62 (2H, s), 4.34 (2H, t, J=7Hz), 2.95-2.54 (3H, m), 2.20-1.57 (6H, m).Example 2(f)

[5-[2-(1-(3-pyridyl)methylideneaminoxy)ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid

TLC: Rf 0.31 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>);NMR:  $\delta$  8.70-8.30 (2H, m), 7.70-7.60 (1H, m), 7.50-7.20 (6H, m), 7.00 (1H, t, J=8Hz), 6.93 (1H, d, J=8Hz), 6.63 (1H, d, J=8Hz), 5.82 (1H, t, J=4Hz), 4.58 (2H, s), 4.27 (2H, t, J=7Hz), 2.85-2.60 (4H, m), 2.25-2.05 (2H, m)Example 2(g)


[5-[2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid

TLC: Rf 0.25 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>);NMR:  $\delta$  8.70-8.40 (2H, m), 7.85-7.75 (1H, m), 7.50-7.20 (6H, m), 7.13 (1H, t, J=8Hz), 6.88 (1H, d, J=8Hz), 6.71 (1H, d, J=8Hz), 5.92 (1H, t, J=4Hz), 4.63 (2H, s), 4.37 (2H, t, J=7Hz), 3.00-2.85 (4H, m), 2.30-2.15 (2H, m)

Example 2(f) and 2(g) are stereo isomers, each other.


Example 2(h)

[5-[2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethylidene]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid

TLC: Rf 0.39 (20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>);NMR:  $\delta$  8.68-8.50 (2H, m), 7.80-7.75 (1H, m), 7.50-7.20 (7H, m), 7.09 (1H, t, J=8Hz), 6.88 (1H, d, J=8Hz), 6.27-6.16 (1H, m), 4.83 (2H, d, J=7Hz), 4.62 (2H, s), 2.63 (2H, t, J=7Hz), 2.63-2.47 (2H, m), 1.83-1.73 (2H, m).

## Example 2(i)

[5-(2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl)-5,8,7,8-tetrahydronaphthalen-1-yloxy]acetic acid



TLC: Rf 0.39 (20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>);  
 NMR:  $\delta$  7.60-7.20 (10H, m), 7.12 (1H, t), 6.82 (1H, d), 6.69 (1H, d), 5.80 (1H, dd), 5.53 (1H, dt), 4.61 (2H, s), 4.31 (2H, d), 3.84 (1H, m), 2.75 (2H, m), 2.00-1.70 (4H, m).

## Formulation example 1

The following components were admixed in conventional method and punched out to obtain 100 tablets each containing 5 mg of active ingredient.

• [5-(2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl)-5,8,7,8-tetrahydronaphthalen-1-yloxy]acetic acid	500 mg
• Carboxymethylcellulose calcium	200 mg
• Magnesium stearate	100 mg
• Micro crystalline cellulose	9.2 g


## Formulation example 2

The following components were admixed in conventional manner. The solution was sterilized in conventional manner, placed 10 ml portion into ampoules and freeze-dried to obtain 100 ampoules each containing 2 mg of the active ingredient.

• [5-(2-(1-phenyl-1-(3-pyridyl)methylideneaminoxy)ethyl)-5,8,7,8-tetrahydronaphthalen-1-yloxy]acetic acid	200 mg
• Mannitol	50 mg
• Distilled water	1000 ml

## Claims




1. An oxime derivative of the formula (i):




wherein



is



or

R<sup>1</sup> is hydrogen or C1-4 alkyl ;R<sup>2</sup> is

- (i) hydrogen,
- (ii) C1-8 alkyl,
- (iii) phenyl or C4-7 cycloalkyl,
- (iv) 4-7 membered monocyclic ring containing one nitrogen,
- (v) C1-4 alkyl substituted by benzene ring or C4-7 cycloalkyl or
- (vi) C1-4 alkyl substituted by 4-7 membered monocyclic ring containing one nitrogen ;

R<sup>3</sup> is


- (i) C1-8 alkyl,
- (ii) phenyl or C4-7 cycloalkyl,

- (iii) 4-7 membered monocyclic ring containing one nitrogen,  
 (iv) C1-4 alkyl substituted by benzene ring or C4-7 cycloalkyl or  
 (v) C1-4 alkyl substituted by 4-7 membered monocyclic ring containing one nitrogen ;  
 e is 3-5, f is 1-3, p is 1-4, q is 1 or 2, r is 1-3 ;  
 with the proviso that, when




is (iii) or (iv),  $-(CH_2)_p-$  and  $=CH-(CH_2)_q-$  is bonded at the position a or b on the ring, and the ring in R<sup>2</sup> and R<sup>3</sup> may be substituted by one to three of C1-4 alkyl, C1-4 alkoxy, halogen, nitro or thiomethyl ; and non-toxic salts thereof.

2. A compound according to claim 1, wherein the formula:




is (i)

3. A compound according to claim 1, wherein the formula:




is (ii)

4. A compound according to claim 1, wherein the formula:



is (iii)

5. A compound according to claim 1, wherein the formula:



is (iv)

6. A compound according to claim 1, wherein R<sup>2</sup> is C1-8 alkyl.  
 7. A compound according to claim 1, wherein R<sup>2</sup> is phenyl or C4-7 cycloalkyl.  
 8. A compound according to claim 1, wherein R<sup>2</sup> is heterocyclic mono-ring of 4-7 membered containing one nitrogen.

9. A compound according to claim 1, wherein R<sup>2</sup> is pyridine ring.


10. A compound according to claim 1, wherein R<sup>2</sup> is C1-4 alkyl substituted by phenyl or C4-7 cycloalkyl.

11. A compound according to claim 1, wherein R<sup>2</sup> is C1-4 alkyl substituted by heterocyclic mono-ring of 4-7 membered containing one nitrogen.

12. A compound according to claim 1, which is:


- [5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
 [5-[2-(diphenylmethylideneaminoxy)ethyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
 [1-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-2,3-dihydroinden-4-yloxy]acetic acid,  
 [6-[1-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]methyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
 [6-[1-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]methyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid,  
 [5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid,  
 [5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid,  
 [5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethylidene)-5,6,7,8-tetrahydronaphthalen-1-yloxy]-acetic acid or  
 [5-[3-(diphenylmethylideneaminoxy)-1-propenyl]-5,6,7,8-tetrahydronaphthalen-1-yloxy]acetic acid.

13. A process for the preparation of the compound of the formula:



(i)

- wherein R1a is C1-4 alkyl and the other symbols are the same meaning as defined in claim 1; which is characterized by reacting a compound of the formula:



(ii)

wherein X is halogen or mesyloxy, and the other symbols are the same meaning as hereinbefore defined;  
 and a compound of formula (iii) :



wherein all the symbols are the same meaning as hereinbefore defined, and further, if necessary, subjecting with hydrolysis in an alkaline condition and/or reduction.

14. A pharmaceutical composition which comprises, as active ingredient, an effective amount of a compound of the formula (I) depicted in claim 1 or pharmaceutically acceptable salts thereof, with a pharmaceutical carrier or coating.

15. For use in the prevention and/or the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer or hypertension, which comprises the administration of an effective amount of a compound of the formula (I) depicted in claim 1 or pharmaceutically acceptable salts thereof.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 93 11 1689

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Classification of documents with indication, where appropriate, of relevant passages	Reference to claims	CLASSIFICATION OF THE APPLICATION (see Cl. 1)
A, P	EP-A-0 542 203 (ONO PHARMACEUTICAL CO., LTD.) * claim 1 *	1	C07C251/54 C07C239/20 C07D213/53 C07D401/06
A, P	CHEMICAL ABSTRACTS, vol. 118, 1993, Columbus, Ohio, US; abstract no. 191350b, * abstract * & JP-A-04 334 358 (ONO YAKUHIN KOGYO K.K.) 20 November 1992	1	
A	EP-A-0 043 292 (NATIONAL RESEARCH DEVELOPMENT) * page 1; claim 1 *	1	
			TECHNICAL FIELDS SEARCHED (see Cl. 1)
			C07C C07D
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	
BERLIN		11 OCTOBER 1993	
Examiner		KAPTEYN H.	
CATEGORY OF CITED DOCUMENTS			
T : claim or principle underlying the invention E : earlier patent document, not published in, or published in, the language of the application D : document cited in the application L : document cited for other reasons A : document of the same category O : non-patent literature P : intermediate document			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**